Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

Right first digit, pre-treatment (left) and after 60 days (2 infiltrations), 1 infiltration every 30 days (right) Connective Tissue Disease Unit, Dermatology Service, Universidade de Santo Amaro, São ...

Daromun (L19-IL2 + L19-TNF) is under development for the treatment of metastatic melanoma, non-melanomatous skin cancer including basal cell carcinoma (basal cell epithelioma), squamous cell carcinoma ...

Medically reviewed by William Truswell, MD Actinic cheilitis (AC) is a precancerous lip lesion caused by ultraviolet (UV) ...